Loading...

SKYE SKYE BIOSCIENCE INC Operational Disruptions 8-K Filing

SKY

SKY

SKYE BIOSCIENCE INC

(SKYE)

2024 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Equity Incentive Update

Financial Results

Management Changes

Incentive Plan Update

Director Appointment and Re...

Clinical Trial Discontinuation

Pro Forma Balance Sheet

Securities Purchase Agreement

Director Appointment and Re...

Securities Purchase Agreement

Agreement, Sale, Termination

Amendment to Articles of In...

Amendment to Incentive Plan

Merger of Equals

Agreement with Emerald Heal...

Resignation and Appointment...

Acquisition of Verd lite Sc...

Stock Purchase Agreement Am...

Amendment and Appointment

External Links:

Skye Bioscience, Inc. announced that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion did not meet its primary endpoint for lowering intraocular pressure, leading to the discontinuation of the clinical development of SBI-100 OE and the redi

AI Assistant

SKYE BIOSCIENCE INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.